ADC Therapeutics(ADCT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, net product revenues were $22.3 million, up from $16.4 million in Q4 2024, indicating a strong performance [21] - For the full year 2025, net product revenues reached $73.6 million, compared to $69.3 million in 2024, showing stability in revenue generation [21] - Total operating expenses for Q4 2025 were $41 million, while for the full year, they were $202.9 million, reflecting a disciplined approach to cost management [21][22] - The net loss for Q4 2025 was $6.4 million, significantly reduced from a loss of $30.7 million in Q4 2024 [22][23] Business Line Data and Key Metrics Changes - The focus on ZYNLONTA has led to a refined go-to-market model, maintaining its position in the third-line plus DLBCL setting despite increased competition from bispecific therapies [5][6] - The company anticipates significant growth opportunities in the second-line plus DLBCL setting with LOTIS-5, expecting to share top-line data in Q2 2026 [8][10] Market Data and Key Metrics Changes - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, impacting market dynamics [15] - The company estimates that achieving a 10% market share in the second-line setting could translate to an additional $200 million to $300 million in revenue [20] Company Strategy and Development Direction - The strategic plan focuses on optimizing lifecycle management for ZYNLONTA, including advancing LOTIS-5 and initiating LOTIS-7 [5][6] - The company aims to establish ZYNLONTA as a backbone therapy in DLBCL, targeting peak annual revenues of $600 million to $1 billion with regulatory approvals and compendia listings [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's path forward, highlighting a strengthened balance sheet and a cash runway expected to last into 2028 [10][24] - The anticipated data catalysts in 2026 are expected to drive significant long-term growth, particularly with the LOTIS-5 and LOTIS-7 trials [25][26] Other Important Information - The company has successfully reduced its operating cost structure by approximately 50%, enhancing its strategic flexibility [5][6] - The amendment to the royalty purchase agreement with HealthCare Royalty reflects the company's confidence in ZYNLONTA's long-term value [9][10] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [29][30] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in the second-line plus DLBCL market, with potential for higher peak sales depending on clinical outcomes [34][35] Question: What is the expected R&D spend moving forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [42][44] Question: How will capital allocation priorities be managed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities [48][50] Question: What is the current commercial run rate for ZYNLONTA? - The company has maintained its market share despite increased competition, with expectations for significant sales growth following LOTIS-5 approval [58][59]